Analysts expect that ENDRA Life Sciences Inc (NASDAQ:NDRA) will announce ($0.21) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ENDRA Life Sciences’ earnings. ENDRA Life Sciences posted earnings per share of ($0.31) in the same quarter last year, which indicates a positive year-over-year growth rate of 32.3%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 13th.
According to Zacks, analysts expect that ENDRA Life Sciences will report full-year earnings of ($0.82) per share for the current financial year. For the next financial year, analysts expect that the firm will report earnings of ($0.58) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for ENDRA Life Sciences.
ENDRA Life Sciences (NASDAQ:NDRA) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.29) EPS for the quarter, hitting the consensus estimate of ($0.29).
NASDAQ:NDRA traded down $0.03 during mid-day trading on Friday, hitting $0.93. 901,000 shares of the company’s stock were exchanged, compared to its average volume of 230,386. ENDRA Life Sciences has a one year low of $0.60 and a one year high of $2.25. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.43 and a quick ratio of 2.32. The business has a fifty day moving average price of $0.86 and a 200 day moving average price of $1.10. The company has a market cap of $13.93 million, a PE ratio of -0.41 and a beta of 1.80.
An institutional investor recently raised its position in ENDRA Life Sciences stock. ICM Asset Management Inc. WA lifted its position in ENDRA Life Sciences Inc (NASDAQ:NDRA) by 32.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 876,639 shares of the company’s stock after buying an additional 212,755 shares during the period. ENDRA Life Sciences comprises 0.6% of ICM Asset Management Inc. WA’s portfolio, making the stock its 21st largest holding. ICM Asset Management Inc. WA owned about 6.37% of ENDRA Life Sciences worth $633,000 at the end of the most recent reporting period. Institutional investors own 7.86% of the company’s stock.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
Further Reading: What is meant by holder of record?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.